A Phase 3 interventional study of cyclosporine and Matched Unrelated Donor Hematopoetic Stem Cell Transplant in Severe Aplastic Anemia, sponsored by Boston Children's Hospital. Terminated at 52 sites in 2 countries. Open to participants aged 0 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Boston Children's Hospital · Phase 3, Interventional, and Treatment
Funding terminated
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing Antilymphocyte Serum in Anemia, Aplastic — 3 open to participants now, 3 under way, none of them phase 3. Antilymphocyte Serum · Anemia, Aplastic.
Among the 20 studies testing Antilymphocyte Serum in Anemia, Aplastic, this one is the 8th largest by enrollment, is the only one that started in 2023, is the only one in phase 3, and was the 18th registered.
373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.
Browse Anemia, Aplastic studies →3 of the 20 studies testing Antilymphocyte Serum in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages up to 75 · Healthy volunteers
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Anhui Provincial Hospital · Sites in China
Ages 1–50
By country, each count listing its studies:
Antilymphocyte Serum: first FDA approval 1996 (Atgam). What it is approved for, and how studies give it, is on its page →
Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.
This study: 0 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 3 · Phase 4 2
First in 1997; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is above the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.
Median enrollment 38 across the 20 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 20 has an industry lead sponsor. The 10 most frequent:
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
Boston Children's Hospital has 2 studies filed under Anemia, Aplastic — fewer than ten, so there is no comparison to draw.
1 of the studies testing Antilymphocyte Serum in Anemia, Aplastic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757310City of Hope Medical CenterA Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia | 2027-06-18 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing Antilymphocyte Serum in Anemia, Aplastic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a secondary treatment in patients who did not get better with IST, had their disease come back, or a new worse disease replaced it (like leukemia).
This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA.
The trial will also assess whether health-related quality of life and early markers of fertility differ between those randomized to URD BMT or IST, as well as assess the presence of marrow failure-related genes and presence of gene mutations associated with MDS or leukemia and the change in gene signatures after treatment in both study arms.
This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for treatment of SAA.
This study is a multi-center randomized phase III trial to compare the failure free survival between those randomized to IST vs 9-10/10 HLA matched URD BMT. The study will also address patient-reported outcomes and gonadal function in each arm and explore critical biological correlates including assessing germline genetic mutations associated with pediatric SAA that may lead to a predisposition to the disease and the risk of development of clonal hematopoiesis following IST vs BMT in pediatric and young adult SAA.
This clinical trial will randomize 234 children/AYA over 3.3-4.7 years at a 1:1 ratio between initial treatment with immune suppression therapy (IST) with horse ATG (hATG)/cyclosporine (CsA) versus well- matched (9-10/10 allele) unrelated donor (URD) bone marrow transplantation (BMT) using a regimen of rabbit ATG (rATG)/fludarabine/cyclophosphamide and 200 cGy TBI. Duration of subject participation for all study procedures in this study will be up to 2 years after treatment; a single later timepoint between 3 and 5 years will be collected to follow patients for specific protocol defined late effects and survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible to participate in the randomized trial, an individual must meet all the following criteria:
Confirmed diagnosis of idiopathic SAA, defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
Drug: cyclosporine · Drug: horse anti-thymocyte globulin (ATG) · Procedure: Immunosuppressive Therapy (IST)
Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
Drug: cyclosporine · Procedure: Matched Unrelated Donor Hematopoetic Stem Cell Transplant · Drug: rabbit anti-thymocyte globulin (ATG) · Drug: Methotrexate · Drug: Fludarabine · Drug: Cyclophosphamide · Radiation: low-dose total body irradiation (TBI)
cyclosporine
Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
horse anti-thymocyte globulin (ATG)
Also known as: ATGAM
rabbit anti-thymocyte globulin (ATG)
Also known as: thymoglobulin
methotrexate
fludarabine
cyclophosphamide
low-dose total body irradiation (TBI)
Immunosuppressive Therapy (IST)
The primary endpoint of this trial is time from randomization to treatment failure or death from any cause.
The median time to failure or death will be compared on the two arms using the log-rank test. Failure of IST is defined as the date that a second definitive therapy was recommended (BMT, second course of ATG) and failure of BMT defined as the date that a second definitive therapy was recommended (second BMT, course of ATG).
Time frame: Randomization to 2 years post-randomization
Comparison of subjects with failure of IST or BMT before or at 2 years
The proportion of subjects with failure of IST or BMT before or at 2 years. Failure of IST is defined as initiation of a second definitive therapy (BMT, second course of ATG) and failure of BMT defined as initiation of a second definitive therapy (second BMT, course of ATG).
Time frame: Randomization to 2 years post-randomization
Comparison of subjects with inadequate counts at 2 years among those who have not died or failed treatment.
The proportion of subjects with inadequate counts at 2 years among those who have not failed therapy or died. Adequate counts are defined as: Absolute Neutrophil Count (ANC) \>1 x 10\^9/L, Hemoglobin \>10g/dL, and Platelets \>50 x10\^9/L.
Time frame: Randomization to 2 years post-randomization
Comparison of subjects on immune suppression therapy at 2 years among those who have not died or failed treatment.
The proportion of subjects on immune suppression therapy at 2 years among those who have not failed therapy or died. Immune suppression is defined as systemic therapies necessary to treat SAA or GVHD (cyclosporine, tacrolimus, etc.). Isolated treatment with topical agents will not be considered as immune suppression therapy.
Time frame: Randomization to 2 years post-randomization
Estimate the time from randomization to initiation of IST or BMT.
The median time in days from randomization to initiation of IST or BMT will be estimated. Initiation of therapy is first day of ATG for IST subjects, or day 0 (infusion day) for bone marrow transplant subjects.
Time frame: Randomization through Day 100
Comparison of the frequency of failure to receive primary assigned therapy (IST or BMT) and reasons for the failure.
The proportion of subjects who fail to receive randomized therapy and the frequency of reasons for failure.
Time frame: Randomization through Day 100
Comparison of the incidence of bacteremia, viremia, and invasive fungal infection in the first two years after randomization in the IST and BMT arms.
Proportion of subjects from the time of randomization in the first 2 years with each of the following: 1. Documented bacteremia 2. Documented viremia 3. Documented invasive fungal infection (defined as confirmed or suspected fungal infection based upon imaging)
Time frame: Randomization through two years post randomization
Estimate the median time to T- and B-cell immune reconstitution the first year for the URD BMT Arm
Absolute CD3, CD4, CD8, CD19, and CD56 (NK cell) numbers will be tracked at 100 days, 180 days, 1 year and 2 years post initiation of therapy in URT BMT arm. IgG levels free of IVIG replacement will be collected at the same timepoints. The median time to T- and B-cell reconstitution will be estimated.
Time frame: Initiation of therapy (Day 0) to 100 days, 180 days, 1 year and 2 years
Comparison of overall survival at 1 and 2 years from randomization in both arms.
Proportion of subjects who have died at 1 year and 2 years after randomization for any reason.
Time frame: Randomization to one year, randomization to two years
Comparison of treatment-related mortality (TRM) at 1 and 2 years from randomization in both arms.
Proportion of subjects who have died at 1 year and 2 years after randomization due to treatment-related reasons. TRM is defined as death in recipients without relapse or progression of their disease. Non-medical, accidental causes of death, e.g., natural disasters, are not considered TRM.
Time frame: Randomization to 1 year, randomization to 2 years
Comparison of the median time from randomization to and rates of neutrophil recovery on both arms
The time from randomization to neutrophil recovery. Neutrophil recovery is defined as ANC 0.5 x109/L for 3 consecutive measures for neutrophils (recovery date is the first date).
Time frame: Randomization to 100 days, 180 days, 1 year and 2 years
Comparison of the median time from randomization to and rate of platelet recovery on both arms
The time from randomization to platelet recovery. Platelet recovery is defined as platelet levels \>= 20 x10\^9/L for 3 consecutive measures (recovery is the first date) with no platelet transfusions for 1 full week.
Time frame: Randomization to 100 days, 180 days, 1 year and 2 years
Comparison of the median time from randomization to and rates of red blood cell recovery on both arms
The time from randomization to red blood cell recovery. Red blood cell recovery is defined as RBC hemoglobin level \>= 8g/dL and 10g/dL with no RBC transfusions for 4 weeks.
Time frame: Randomization to 100 days, 180 days, 1 year and 2 years
Comparison of the median time from initiation of therapy to and rates of neutrophil recovery on both arms
The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to neutrophil recovery. Neutrophil recovery is defined as ANC 0.5 x109/L for 3 consecutive measures for neutrophils (recovery date is the first date).
Time frame: Initiation of therapy to 100 days, 180 days, 1 year and 2 years
Comparison of the median time from initiation of therapy to and rate of platelet recovery on both arms
The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to platelet recovery. Platelet recovery is defined as platelet levels \>= 20 x10\^9/L for 3 consecutive measures (recovery is the first date) with no platelet transfusions for 1 full week.
Time frame: Initiation of therapy to 100 days, 180 days, 1 year and 2 years
Comparison of the median time from initiation of therapy to and rates of red blood cell recovery on both arms.
The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to red blood cell recovery. Red blood cell recovery is defined as RBC hemoglobin level \>= 8g/dL and 10g/dL with no RBC transfusions for 4 weeks.
Time frame: Randomization to 100 days, 180 days, 1 year and 2 years
Estimate the rates of engraftment in patients who are randomized to URD BMT.
Proportion of subjects with engraftment in patients who receive URD BMT.
Time frame: Randomization to 3-5 years
Estimate the rates of primary graft failure in patients who are randomized to URD BMT .
Proportion of subjects with primary graft failure in patients who receive URD BMT. Primary graft failure is defined as failure to achieve neutrophil recovery by Day +28 following a conditioning regimen induced neutrophil nadir \< 0.5 x10\^9/L.
Time frame: Randomization to 3-5 years
Estimate the rates of secondary graft failure in patients who are randomized to URD BMT .
Proportion of subjects with secondary graft failure in patients who receive URD BMT. Secondary graft failure will be defined as a fall in the neutrophil count after documented primary engraftment to \< 0.5 x10\^9/L sustained for more than three days that cannot be attributed to other causes such as drugs, infection, GVHD, etc., and is not responsive to G-CSF or GM-CSF.
Time frame: Randomization to 3-5 years
Estimate the rates of grade II-IV acute GVHD in patients who are randomized to URD BMT .
Proportion of subjects with grade II-IV in patients who receive URD BMT.
Time frame: Randomization to 3-5 years
Estimate the rates of grade III-IV acute GVHD in patients who are randomized to URD BMT.
Proportion of subjects with grade III-IV acute GVHD in patients who receive URD BMT.
Time frame: Randomization to 3-5 years
Estimate the rates of severe chronic GVHD in patients who are randomized to URD BMT.
Proportion of subjects with severe chronic GVHD in patients who receive URD BMT.
Time frame: Randomization to 3-5 years
Estimate the rates of response of patients randomized to IST
Proportion of subjects with IST response. IST response criteria is: Complete Response: Hemoglobin ≥10 g/dL and ANC ≥1x10\^9/L and Platelets ≥100x10\^9/L Very Good Partial Response: Hemoglobin ≥8 g/dL and ANC ≥0.5x10\^9/L and Platelets ≥50x10\^9/L Partial Response: Hemoglobin ≥8 g/dL and ANC ≥0.5x10\^9/L and Platelets ≥20x10\^9/L and transfusion independent No Response (failure): Hemoglobin \<8 g/dL or ANC \<0.5x10\^9/L or Platelets \<20x10\^9/L Lost Response: A lost response is captured by not meeting hematologic response criteria at a particular time point after having an initial response (complete, very good partial, or partial), or the need for additional treatment.
Time frame: Randomization to 100 days, 180 days, 1 year and 2 years
Estimate the rates of failure of patients randomized to IST
Proportion of subjects with IST failure at 6 months (defined as Hemoglobin \<8 g/dL or ANC \<0.5x10\^9/L or Platelets \<20x10\^9/L).
Time frame: Randomization to 100 days, 180 days, 1 year and 2 years
Describe the secondary therapies given and outcomes achieved for patients failing initial therapy
Collect secondary therapies given for failure of primary randomized therapy (BMT after IST, second course of IST, second BMT). For the outcome after subsequent therapy, the median survival time will be estimated.
Time frame: Randomization to 3-5 years
Comparison of rates of secondary MDS, AML, other subsequent neoplasms, and development of Paroxysmal Nocturnal Hemoglobinuria in both treatment arms for the duration of the trial.
Proportion of subjects in each treatment arm with i) subsequent neoplasms, ii) presence of a PNH clone at time of randomization who go on to develop symptomatic PNH through the duration of the protocol.
Time frame: Randomization to 3-5 years
Comparison of HR-QoL score between patients randomized to both arms
Change in score between baseline and two years and the trajectory of change over all timepoints.
Time frame: Randomization to 2 years post-randomization, randomization to up to 5 years post-randomization
Comparison of gonadal function values between patients randomized to both arms
Proportion of subjects with gonadal function values outside the expected percentile for that age.
Time frame: Randomization to 1 year post-randomization, randomization to 2 years post-randomization, and randomization to up to 5 years post-randomization
Ran from Jan 2023 to primary completion in Aug 2026, 42 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2029 → Aug 2026 and completion Dec 2029 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Funding terminated
Funding terminated
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Antilymphocyte Serum · Thymoglobulin · Methotrexate · Fludarabine · Cyclophosphamide